Comparing Dendritic Cells from Cancer Patients and Healthy Donors
Author Information
Author(s): Ghanekar Smita A, Bhatia Sonny, Ruitenberg Joyce J, Rosa Corazon DeLa, Disis Mary L, Maino Vernon C, Maecker Holden T, Waters Cory A
Primary Institution: BD Biosciences Immunocytometry Systems, University of Washington
Hypothesis
Are the phenotypic and functional characteristics of mature dendritic cells derived from cryopreserved PBMC of cancer patients different from those derived from healthy donors?
Conclusion
Monocytes from cryopreserved PBMC of cancer patients can be fully differentiated into mature dendritic cells with similar phenotype and function to those derived from healthy donors.
Supporting Evidence
- Cryopreservation did not significantly affect the majority of the MDDC characteristics.
- Mature MDDC from cancer patients were equivalent in their ability to stimulate T cells compared to those from healthy donors.
- Only two markers, CD86 and COX-2, were significantly affected by cryopreservation.
- Mature MDDC from both groups showed similar levels of IL-12 and COX-2 expression.
Takeaway
Doctors studied immune cells from cancer patients and healthy people to see if they work the same way. They found that the cancer patients' cells can still do their job just as well.
Methodology
Flow cytometry was used to compare the surface and functional markers of mature dendritic cells from healthy donors and cancer patients.
Potential Biases
Potential differences in donor characteristics between healthy and cancer patient groups.
Limitations
The study was retrospective and did not directly compare fresh and cryopreserved samples from the same donors.
Participant Demographics
16 cancer patients (12 females, 4 males) with advanced cancers and 11 healthy donors (8 females, 3 males).
Statistical Information
P-Value
p<0.03
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website